Current methods for attaching targeting ligands to liposomes and nanoparticles

Journal of Pharmaceutical Sciences

Volumn 93, Issue 8, 2004, Pages 1980-1992

  Nobs, Leila ^a   Buchegger, Franz ^b   Gurny, Robert ^a   Allémann, Eric ^a,c  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c Bracco Suisse SA   (Switzerland)

Author keywords

Active targeting; Antibody; Carrier system; Drug targeting; Immunoliposome; Liposome; Nanoparticle; Surface modification

Indexed keywords

AMIDE; CAPROLACTAM; CARBOXYLIC ACID DERIVATIVE; DISTEAROYL N [3 CARBOXYPROPIONOYL POLY(ETHYLENE GLYCOL)SUCCINYL]PHOSPHATIDYLETHANOLAMINE; DISTEAROYLPHOSPHATIDYLETHANOLAMINE; GELATIN; GLIADIN; HUMAN SERUM ALBUMIN; IMMUNOLIPOSOME; LIGAND; LIPOSOME; MACROGOL; MALEIMIDE DERIVATIVE; MALEIMIDOPHENYLPROPIONATE; MONOCLONAL ANTIBODY; N GLUTARYLPHOSPHATIDYLETHANOLAMINE; NANOPARTICLE; PEPTIDE DERIVATIVE; POLY(ETHYL 2 CYANOACRYLATE); POLYLACTIC ACID; STYRENE DERIVATIVE; SUCCINIMIDYL 4 (4 MALEIMIDOPHENYL)BUTYRATE; UNCLASSIFIED DRUG;

DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; DRUG TARGETING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; REACTION ANALYSIS; SHORT SURVEY; SURFACE PROPERTY;

EID: 3843112386     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20098     Document Type: Article

References (101)

1. Weiner LM. 2003. Monoclonal antibody therapy of cancer. Semin Oncol 26:43-51.
2. Martin FJ. 1998. Clinical pharmacology and antitumor efficacy of DOXIL (pegylated liposomal doxorubicin). In: Lasic DD, Papahadjopoulos D, editors. Medical applications of liposomes. New York: Elsevier Science B.V., pp 635-688.
3. Allémann E, Gurny R, Doelker E. 1993. Drug-loaded nanoparticles-preparation methods and drug targeting issues. Eur J Pharm Biopharm 39:173-191.
4. Senior JH. 1987. Fate and behavior of liposomes in vivo: A review of controlling factors. Crit Rev Ther Drug Carrier Syst 3:123-193.
5. Stolnik S, Dunn SE, Garnett MC, Davies MC, Coombes AG, Taylor DC, Irving MP, Purkiss SC, Tadros TF, Davis SS. 1994. Surface modification of poly(lactide-co-glycolide) nanospheres by biodegradable poly(lactide)- poly(ethylene glycol) copolymers. Pharm Res 11:1800-1808.
6. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R. 1994. Biodegradable long-circulating polymeric nanospheres. Science 263:1600-1603.
7. Allen TM, Hansen C, Martin F, Redemann C, Yau-Young A. 1991. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta 1066:29-36.
8. Klibanov AL, Maruyama K, Torchilin VP, Huang L. 1990. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEES Lett 268:235-237.
9. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, Lee KD, Woodle MC, Lasic DD, Redemann C. 1991. Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 88:11460-11464.
10. Vaage J, Barbera-Guillem E, Abra R, Huang A, Working P. 1994. Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts. Cancer 73:1478-1484.
11. Northfelt DW, Martin FJ, Working P, Volberding PA, Russell J, Newman M, Amantea MA, Kaplan LD. 1996. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: Pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol 36:55-63.
12. Harasym TO, Bally MB, Tardi P. 1998. Clearance properties of liposomes involving conjugated proteins for targeting. Adv Drug Deliv Rev 32:99-118.
13. Forssen E, Willis M. 1998. Ligand-targeted liposomes. Adv Drug Deliv Rev 29:249-271.
14. Meers P. 2001. Enzyme-activated targeting of liposomes. Adv Drug Deliv Rev 53:265-272.
15. Sihorkar V, Vyas SP. 2001. Potential of polysaccharide anchored liposomes in drug delivery, targeting and immunization. J Pharm Sci 4:138-158.
16. Crommelin DJA, Scherphof G, Storm G. 1995. Active targeting with particulate carrier systems in the blood compartment. Adv Drug Deliv Rev 17:49-60.
17. Maruyama K, Ishida O, Takizawa T, Moribe K. 1999. Possibility of active targeting to tumor tissues with liposomes. Adv Drug Deliv Rev 40:89-102.
18. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. 1999. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 51:691-743.
19. Park JW, Hong K, Kirpotin DB, Papahadjopoulos D, Benz CC. 1997. Immunoliposomes for cancer treatment. Adv Pharmacol 40:399-435.
20. Hughes BJ, Kennel S, Lee R, Huang L. 1989. Monoclonal antibody targeting of liposomes to mouse lung in vivo. Cancer Res 49:6214-6220.
21. Huang A, Huang L, Kennel SJ. 1980. Monoclonal antibody covalently coupled with fatty acid. J Biol Chem 255:8015-8018.
22. Harsch M, Walther P, Weder HG. 1981. Targeting of monoclonal antibody-coated liposomes to sheep red blood cells. Biochem Biophys Res Commun 103:1069-1076.
23. Shen DF, Huang A, Huang L. 1982. An improved method for covalent attachment of antibody to liposomes. Biochim Biophys Acta 689:31-37.
24. Carpenter-Green S, Huang L. 1983. Incorporation of acylated wheat germ agglutinin into liposomes. Anal Biochem 135:151-155.
25. Weissig V, Lasch J, Klibanov AL, Torchilin VP. 1986. A new hydrophobic anchor for the attachment of proteins to liposomal membranes. FEBS Lett 202:86-90.
26. Torchilin VP, Klibanov AL, Smirnov VN. 1982. Phosphatidylinositol may serve as the hydrophobic anchor for immobilization of proteins on liposome surface. FEBS Lett 138:117-120.
27. Torchilin VP, Omel'yanenko VG, Klibanov AL, Mikhailov AI, Gol'danskii VI, Smirnov VN. 1980. Incorporation of hydrophilic protein modified with hydrophobic agent into liposome membrane. Biochim Biophys Acta 602:511-521.
28. Nobs L, Buchegger F, Gurny R, Allémann E. Attachment of homing moities to colloidal carriers for active targeting: Comparison of different coupling methods. In: Benita S, editor. Microencapsulation methods and industrial applications, 2nd ed. New York: Marcel Dekker (in press).
29. Crosasso P, Brusa P, Dosio F, Arpicco S, Pacchioni D, Schuber F, Cattel L. 1997. Antitumoral activity of liposomes and immunoliposomes containing 5-fluorouridine prodrugs. J Pharm Sci 86:832-839.
30. Derksen JT, Scherphof GL. 1985. An improved method for the covalent coupling of proteins to liposomes. Biochim Biophys Acta 814:151-155.
31. Derksen JT, Morselt HW, Scherphof GL. 1988. Uptake and processing of immunoglobulin-coated liposomes by subpopulations of rat liver macrophages. Biochim Biophys Acta 971:127-136.
32. Martin FJ, Papahadjopoulos D. 1982. Irreversible coupling of immunoglobulin fragments to preformed vesicles. An improved method for liposome targeting. J Biol Chem 257:286-288.
33. Nassander UK, Steerenberg PA, De Jong WH, Van Overveld WO, Te Boekhorst CM, Poels LG, Jap PH, Storm G. 1995. Design of immunoliposomes directed against human ovarian carcinoma. Biochim Biophys Acta 1235:126-139.
34. Koning GA, Morselt HW, Velinova MJ, Donga J, Gorter A, Allen TM, Zalipsky S, Kamps JA, Scherphof GL. 1999. Selective transfer of a lipophilic prodrug of 5-fluorodeoxyuridine from immunoliposomes to colon cancer cells. Biochim Biophys Acta 1420:153-167.
35. Park JW, Hong K, Carter P, Asgari H, Guo LY, Keller GA, Wirth C, Shalaby R, Kotts C, Wood WI, Papahadjopoulos D, Benz CC. 1995. Development of anti-p185HER2 immunoliposomes for cancer therapy. Proc Natl Acad Sci USA 92:1327-1331.
36. Nassander UK, Steerenberg PA, Poppe H, Storm G, Poels LG, De Jong WH, Crommelin DJ. 1992. In vivo targeting of OV-TL 3 immunoliposomes to ascitic ovarian carcinoma cells (OVCAR-3) in athymic nude mice. Cancer Res 52:646-653.
37. Vingerhoeds MH, Steerenberg PA, Hendriks JJ, Dekker LC, Van Hoesel QG, Crommelin DJ, Storm G. 1996. Immunoliposome-mediated targeting of doxorubicin to human ovarian carcinoma in vitro and in vivo. Br J Cancer 74:1023-1029.
38. Park JW, Hong K, Kirpotin DB, Meyer O, Papahadjopoulos D, Benz CC. 1997. Anti-HER2 immunoliposomes for targeted therapy of human tumors. Cancer Lett 118:153-160.
39. Mercadal M, Domingo JC, Petriz J, Garcia J, de Madariaga MA. 1999. A novel strategy affords high-yield coupling of antibody to extremities of liposomal surface-grafted PEG chains. Biochim Biophys Acta 1418:232-238.
40. Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, Papahadjopoulos D, Benz CC. 2002. Anti-HER2 immunoliposomes: Enhanced efficacy attributable to targeted delivery. Clin Cancer Res 8:1172-1181.
41. Kirpotin D, Park JW, Hong K, Zalipsky S, Li WL, Carter P, Benz CC, Papahadjopoulos D. 1997. Sterically stabilized anti-HER2 immunoliposomes: Design and targeting to human breast cancer cells in vitro. Biochemistry 36:66-75.
42. Hansen CB, Kao GY, Moase EH, Zalipsky S, Allen TM. 1995. Attachment of antibodies to sterically stabilized liposomes: Evaluation, comparison and optimization of coupling procedures. Biochim Biophys Acta 1239:133-144.
43. Allen TM, Brandeis E, Hansen CB, Kao GY, Zalipsky S. 1995. A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim Biophys Acta 127:99-108.
44. Carrion C, Domingo JC, de Madariaga MA. 2001. Preparation of long-circulating immunoliposomes using PEG-cholesterol conjugates: Effect of the spacer arm between PEG and cholesterol on liposomal characteristics. Chem Phys Lipids 113:97-110.
45. Martin FJ, Hubbell WL, Papahadjopoulos D. 1981. Immunospecific targeting of liposomes to cells: a novel and efficient method for covalent attachment of Fab' fragments via disulfide bonds. Biochemistry 20:4229-4238.
46. Ivanov VO, Preobrazhensky SN, Tsibulsky VP, Babaev VR, Repin VS, Smirnov VN. 1985. Liposome uptake by cultured macrophages mediated by modified low-density lipoproteins. Biochim Biophys Acta 846:76-84.
47. Leserman LD, Barbet J, Kourilsky F, Weinstein JN. 1980. Targeting to cells of fluorescent liposomes covalently coupled with monoclonal antibody or protein A. Nature 288:602-604.
48. Ishida O, Maruyama K, Tanahashi H, Iwatsuru M, Sasaki K, Eriguchi M, Yanagie H. 2001. Liposomes bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumors in vivo. Pharm Res 18:1042-1048.
49. Maruyama K, Takizawa T, Yuda T, Kennel SJ, Huang L, Iwatsuru M. 1995. Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies. Biochim Biophys Acta 1234:74-80.
50. Maruyama K, Holmberg E, Kennel SJ, Klibanov A, Torchilin VP, Huang L. 1990. Characterization of in vivo immunoliposome targeting to pulmonary endothelium. J Pharm Sci 79:978-984.
51. Torchilin VP, Klibanov AL, Huang L, O'Donnell S, Nossiff ND, Khaw BA. 1992. Targeted accumulation of polyethylene glycol-coated immunoliposomes in infarcted rabbit myocardium. FASEB J 6:2716-2719.
52. Torchilin VP, Narula J, Halpern E, Khaw BA. 1996. Poly(ethylene glycol)-coated anti-cardiac myosin immunoliposomes: Factors influencing targeted accumulation in the infarcted myocardium. Biochim Biophys Acta 1279:75-83.
53. Holmberg E, Maruyama K, Litzinger DC, Wright S, Davis M, Kabalka GW, Kennel SJ, Huang L. 1989. Highly efficient immunoliposomes prepared with a method which is compatible with various lipid compositions. Biochem Biophys Res Commun 165:1272-1278.
54. Khaw BA, daSilva J, Vural I, Narula J, Torchilin VP. 2001. Intracytoplasmic gene delivery for in vitro transfection with cytoskeleton-specific immunoliposomes. J Controlled Release 75:199-210.
55. Torchilin VP, Levchenko TS, Lukyanov AN, Khaw BA, Klibanov AL, Rammohan R, Samokhin GP, Whiteman KR. 2001. p-Nitrophenylcarbonyl-PEG-PE-liposomes: Fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups. Biochim Biophys Acta 1511:397-411.
56. Blume G, Cevc G, Crommelin MD, Bakker-Woudenberg IA, Kluft C, Storm G. 1993. Specific targeting with poly(ethylene glycol)-modified liposomes: Coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times. Biochim Biophys Acta 1149:180-184.
57. Chua MM, Fan ST, Karush F. 1984. Attachment of immunoglobulin to liposomal membrane via protein carbohydrate. Biochim Biophys Acta 800:291-300.
58. Harding JA, Engbers CM, Newman MS, Goldstein NI, Zalipsky S. 1997. Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes. Biochim Biophys Acta 1327:181-192.
59. Goren D, Horowitz AT, Zalipsky S, Woodle MC, Yarden Y, Gabizon A. 1996. Targeting of stealth liposomes to erbB-2 (Her/2) receptor: In vitro and in vivo studies. Br J Cancer 74:1749-1756.
60. Lopes de Menezes DE, Pilarski LM, Allen TM. 1998. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res 58:3320-3330.
61. Zalipsky S. 1993. Synthesis of an end-group functionalized polyethylene glycol-lipid conjugate for preparation of polymer-grafted liposomes. Bioconjug Chem 4:296-299.
62. Torchilin VP, Khaw BA, Smirnov VN, Haber E. 1979. Preservation of antimyosin antibody activity after covalent coupling to liposomes. Biochem Biophys Res Commun 89:1114-1119.
63. Torchilin VP, Goldmacher VS, Smirnov VN. 1978. Comparative studies on covalent and noncovalent immobilization of protein molecules on the surface of liposomes. Biochem Biophys Res Commun 85:983-990.
64. Magnani P, Paganelli G, Modorati G, Zito F, Songini C, Sudati F, Koch P, Maecke HR, Brancato R, Siccardi AG, Fazio F. 1996. Quantitative comparison of direct antibody labeling and tumor pretargeting in uveal melanoma. J Nucleic Med 37:967-971.
65. Casalini P, Luison E, Ménard S, Colnaghi MI, Paganelli G, Canevari S. 1997. Tumor pretargeting: Role of avidin/streptavidin on monoclonal antibody internalization. J Nucleic Med 38:1378-1381.
66. Moro M, Pelagi M, Fulci G, Paganelli G, Dellabona P, Casorati G, Siccardi AG, Corti A. 1997. Tumor cell targeting with antibody-avidin complexes and biotinylated tumor necrosis factor a1. Cancer Res 57:1922-1928.
67. Loughrey H, Bally MB, Cullis PR. 1987. A non-covalent method of attaching antibodies to liposomes. Biochim Biophys Acta 901:157-160.
68. Mao SY. 1994. Biotinylation of antibodies. Methods Mol Biol 34:49-52.
69. Portnoy J, Brothers D, Pacheco F, Landuyt J, Barnes C. 1998. Monoclonal antibody-based assay for Alt a1, a major Alternaria allergen. Ann Allergy Asthma Immunol 81:59-64.
70. Pieri I, Barritault D. 1991. Biotinylated basic fibroblast growth factor is biologically active. Anal Biochem 195:214-219.
71. Xiao Z, McQuarrie SA, Suresh MR, Mercer JR, Gupta S, Miller GG. 2002. A three-step strategy for targeting drug carriers to human ovarian carcinoma cells in vitro. J Biotechnol 94:171-184.
72. Huang L, Kennel SJ. 1979. Binding of immunoglobulin G to phospholipid vesicles by sonication. Biochemistry 18:1702-1707.
73. Weissmann G, Brand A, Franklin EC. 1974. Interaction of immunoglobulins with liposomes. J Clin Invest 53:536-543.
74. Weissmann G, Bloomgarden D, Kaplan R, Cohen C, Hoffstein S, Collins T, Gotlieb A, Nagle D. 1975. A general method for the introduction of enzymes, by means of immunoglobulin-coated liposomes, into lysosomes of deficient cells. Proc Natl Acad Sci USA 72:88-92.
75. Leserman LD, Weinstein JN, Blumenthal R, Sharrow SO, Terry WD. 1979. Binding of antigen-bearing fluorescent liposomes to the murine myeloma tumor MOPC 315. J Immunol 122:585-591.
76. Leserman LD, Weinstein JN, Blumenthal R, Terry WD. 1980. Receptor-mediated endocytosis of antibody-opsonized liposomes by tumor cells. Proc Natl Acad Sci USA 77:4089-4093.
77. Leserman LD, Weinstein JN, Moore JJ, Terry WD. 1980. Specific interaction of myeloma tumor cells with hapten-bearing liposomes containing methotrexate and carboxyfluorescein. Cancer Res 40:4768-4774.
78. Weinstein JN, Blumenthal R, Sharrow SO, Henkart PA. 1978. Antibody-mediated targeting of liposomes. Binding to lymphocytes does not ensure incorporation of vesicle contents into the cells. Biochim Biophys Acta 509:272-288.
79. Moghimi SM, Hunter AC, Murray JC. 2001. Long-circulating and target-specific nanoparticles: Theory to practice. Pharmacol Rev 53:283-318.
80. Illum L, Jones PD, Baldwin RW, Davis SS. 1984. Tissue distribution of poly(hexyl 2-cyanoacrylate) nanoparticles coated with monoclonal antibodies in mice bearing human tumor xenografts. J Pharmacol Exp Ther 230:733-736.
81. Illum L, Jones PDE, Kreuter J, Baldwin RW, Davis SS. 1983. Adsorption of monoclonal antibodies to polyhexylcyanoacrylate nanoparticles and subsequent immunospecific binding to tumour cells in vitro. Int J Pharm 17:65-76.
82. Kubiak C, Manil L, Couvreur P. 1988. Sorptive properties of antibodies onto cyanoacrylic nanoparticles. Int J Pharm 41:181-187.
83. Manil L, Roblot-Treupel L, Couvreur P. 1986. Isobutyl cyanoacrylate nanoparticles as a solid phase for an efficient immunoradiometric assay. Biomaterials 7:212-216.
84. Couvreur P, Aubry J. 1983. Monoclonal antibodies for the targeting of drugs: Application to nanoparticles. In: Breimer DD, Speises P, editors. Topics in Pharmaceutical Sciences. Amsterdam: Elsevier Sciences Publishers BV, p 305-316.
85. Blackwell JE, Dagia NM, Dickerson JB, Berg EL, Goetz DJ. 2001. Ligand coated nanosphere adhesion to E- and P-selectin under static and flow conditions. Ann Biomed Eng 29:523-533.
86. Akasaka Y, Ueda H, Takayama K, Machida Y, Nagai T. 1988. Preparation and evaluation of bovine serum albumin nanospheres coated with monoclonal antibodies. Drug Des Deliv 3:85-97.
87. Rolland A, Bourel D, Genetet B, Le Verge R. 1987. Monoclonal antibodies covalently coupled to polymethacrylic nanoparticles: in vitro specific targeting to human T lymphocytes. Int J Pharm 39:173-180.
88. Li Y, Ogris M, Wagner E, Pelisek J, Rüffer M. 2003. Nanoparticles bearing polyethylenglycol-coupled transferrin as gene carriers: preparation and in vitro evaluation. Int J Pharm 259:93-101.
89. Ezpeleta I, Arangoa MA, Irache JM, Stainmesse S, Chabenat C, Popineau Y, Orecchioni AM. 1999. Preparation of Ulex europaeus lectin-gliadin nanoparticle conjugates and their interaction with gastrointestinal mucus. Int J Pharm 191:25-32.
90. Irache JM, Durrer C, Duchêne D, Ponchel G. 1994. Preparation and characterization of lectin-latex conjugates for specific bioadhesion. Biomaterials 15:899-904.
91. Hussain N, Jani PU, Florence AT. 1997. Enhanced oral uptake of tomato lectin-conjugated nanoparticles in the rat. Pharm Res 14:613-618.
92. Gautier S, Grudzielski N, Goffinet G, de Hassonville SH, Delattre L, Jérôme R. 2001. Preparation of poly(D,L-lactide) nanoparticles assisted by amphiphilic poly(methyl methacrylate-co-methacrylic acid) copolymers. J Biomater Sci Polym Ed 12:429-450.
93. Maruyama A, Ishihara T, Kim JS, Kim SW, Akaike T. 1997. Nanoparticle DNA carrier with poly(L-lysine) grafted polysaccharide copolymer and poly(D,L-lactic acid). Bioconjug Chem 8:735-742.
94. Serizawa T, Uchida T, Akashi M. 1999. Synthesis of polystyrene nanospheres having lactose-conjugated hydrophilic polymers on their surfaces and carbohydrate recognition by proteins. J Biomater Sci Polym Ed 10:391-401.
95. Nobs L, Buchegger F, Gurny R, Allémann E. 2003. Surface modification of polydactic acid) nanoparticles by covalent attachment of thiol groups by means of three methods. Int J Pharm 250:327-337.
96. Langer K, Coester C, Weber C, Von Briesen H, Kreuter J. 2000. Preparation of avidin-labeled protein nanoparticles as carriers for biotinylated peptide nucleic acid. Eur J Pharm Biopharm 49:303-307.
97. Coester C, Kreuter J, Von Briesen H, Langer K. 2000. Preparation of avidin-labelled gelatin nanoparticles as carriers for biotinylated peptide nucleic acid (PNA). Int J Pharm 196:147-149.
98. Gref R, Couvreur P, Barratt G, Mysiakine E. 2003. Surface-engineered nanoparticles for multiple ligand coupling. Biomaterials 24:4529-4537.
99. Ishida O, Maruyama K, Sasaki K, Iwatsuru M. 1999. Size-dependent extravasation and interstitial localization of polyethyleneglycol liposomes in solid tumor-bearing mice. Int J Pharm 190:49-56.
100. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, Jain RK. 1998. Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment. Proc Natl Acad Sci USA 95:4607-4612.
101. Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP, Jain RK. 1995. Vascular permeability in human tumor xenograft: Molecular size dependence and cutoff size. Cancer Res 55:3752-3756.